Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | USP2 | O75604 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | CASP1 | P29466 | 2/20 | 0.58 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 2/20 | 0.58 |
| ▸ | CASP7 | P55210 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | HAT1 | O14929 | 2/20 | 0.58 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.58 |
| ▸ | TST | Q16762 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22071682 | 1.00 | KMT2A (0.58) | KMT2AMEN1USP2KDM4EMAPT | |
| SCHEMBL22071670 | 1.00 | KMT2A (0.58) | KMT2AMEN1USP2KDM4EMAPT | |
| SCHEMBL22071679 | 0.90 | MEN1 (0.59) | KMT2AMEN1USP2KDM4EMAPT | |
| SCHEMBL16239990 | 0.90 | MEN1 (0.59) | KMT2AMEN1USP2KDM4EMAPT | |
| Water SCHEMBL16240843 | 0.89 | MEN1 (0.58) | KMT2AMEN1USP2KDM4EMAPT | |
| SCHEMBL22071681 | 0.87 | USP2 (0.56) | KMT2AMEN1USP2KDM4EMAPT | |
| SCHEMBL22071673 | 0.87 | USP2 (0.56) | KMT2AMEN1USP2KDM4EMAPT | |
| SCHEMBL22071729 | 0.86 | MEN1 (0.53) | KMT2AMEN1USP2KDM4EMAPT | |
| SCHEMBL22071680 | 0.86 | MEN1 (0.55) | KMT2AMEN1USP2KDM4EMAPT | |
| SCHEMBL22071669 | 0.86 | MEN1 (0.55) | KMT2AMEN1USP2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214947-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | CUREVERSE INCORPORATED (KR) | 2025-07-03 | — | — | US | claimed |
| EP-4501917-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2025-02-05 | — | — | EP | claimed |
| CN-119301103-A | 3, 4-Dihydroquinoxaline-2-carboxamide derivative compound and pharmaceutical composition for preventing or treating cancer diseases comprising the same | 财团法人 大邱庆北尖端医疗产业振兴财团 | 2025-01-10 | — | — | CN | claimed |
| WO-2023191379-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | 재단법인 대구경북첨단의료산업진흥재단 | 2023-10-05 | — | — | WO | claimed |
| US-20250214947-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | CUREVERSE INCORPORATED (KR) | 2025-07-03 | — | — | US | disclosed |
| EP-4501917-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2025-02-05 | — | — | EP | disclosed |
| CN-119301103-A | 3, 4-Dihydroquinoxaline-2-carboxamide derivative compound and pharmaceutical composition for preventing or treating cancer diseases comprising the same | 财团法人 大邱庆北尖端医疗产业振兴财团 | 2025-01-10 | — | — | CN | disclosed |
| WO-2023191379-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | 재단법인 대구경북첨단의료산업진흥재단 | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214947-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | HDAC8, HDAC1, HDAC5 | KMT2A 54/4885MEN1 3325/4885USP2 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.